Profitability
Weight: 20%
B-
66
- 5yr Avg ROIC 8.4%
- Operating Margin Trend +2.67 pp/yr
AMRX
Amneal Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
6
- 5yr Avg ROE 0.0%
- 5yr Share-Count CAGR 20.9%
Growth Quality
Weight: 15%
A
90
- 5yr Revenue CAGR 9.6%
- 5yr EPS CAGR 33.1%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 15%
C+
62
- 5yr FCF Margin 7.3%
- 5yr FCF/NI Conversion 11.01x
Balance Sheet
Weight: 20%
D-
31
- Net Debt / EBITDA 4.02x
- Interest Coverage (EBIT/Int) 1.58x
- Altman Z-Score 2.11
Stability
Weight: 15%
C
54
- EPS Volatility (σ/μ) 0.73
- Piotroski F-Score 7
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 new buy; 1 added; 1 trimmed.
- Holders
- 3 +1
- Avg Δ position
- -10.6%
- New buys
- 1
- Full exits
- 0
- Wood new
- Cooperman decreased -35%
- Greenblatt increased +14%